TROP2 ADC + BP102

TROP2 ADC + BP102 is a combination therapy consisting of a TROP2-targeted antibody-drug conjugate (ADC) and BP102. TROP2 ADCs are engineered biologic drugs that combine an anti-TROP2 monoclonal antibody with a cytotoxic payload via a chemical linker. The antibody component specifically binds to the trophoblast cell surface antigen 2 (TROP-2), which is highly expressed in various solid tumors, including breast, lung, gastric, colorectal, pancreatic, and prostate cancers[1][3]. Upon binding to tumor cells expressing TROP-2, the ADC is internalized and releases its cytotoxic payload inside the cancer cell—commonly topoisomerase I inhibitors or other potent chemotherapeutics—leading to targeted tumor cell death while sparing most normal tissues[1][3]. BP102's identity and mechanism are not specified in available sources; thus its contribution to this combination cannot be described in detail.